Kinase News and Research

RSS

Defects in cerebrospinal fluid flow may contribute to scoliosis during adolescence

A new study in zebrafish suggests that irregular fluid flow through the spinal column brought on by gene mutations is linked to a type of scoliosis that can affect humans during adolescence.

13 Jun 2016

Researchers identify promising new compound for targeting triple-negative breast cancer

Researchers at the University of Michigan have identified a promising new compound for targeting one of the most aggressive types of breast cancer.

9 Jun 2016

New study identifies PDGFRα as key molecule for HCMV viral entry

A publication in the scientific journal Nature Microbiology identifies PDGFRα as the receptor for the trimeric gHgLgO complex of Human cytomegalovirus (HCMV).

7 Jun 2016

Researchers prove existence of olfactory receptor in pigment-producing skin cells

Researchers at Ruhr-Universität Bochum were the first ones to prove the existence of an olfactory receptor in pigment-producing cells in human skin, the so-called melanocytes. The team headed by Prof Dr Dr Dr habil. Hanns Hatt demonstrated that the violet-like scent Beta-Ionone can activate the receptor.

4 Jun 2016

Mayo study finds mechanism by which Pten safeguards against tumor formation

Pten (short for phosphatase and tensin homolog) is a tumor suppressor that is defective in about 20-25 percent of all patients with cancers. Mayo Clinic researchers now have discovered that Pten safeguards against tumor formation by keeping chromosome numbers intact when a cell splits into two daughter cells.

3 Jun 2016

Analysing blood metabolites may help monitor effects of novel drugs

Testing for metabolic changes in the blood could indicate whether a cancer drug is working as designed, a new study reports.

3 Jun 2016

Understanding how opiates affect brain pathways to drive addiction cycle

New research by Steven Laviolette's research team at Western University is contributing to a better understanding of the ways opiate-class drugs modify brain circuits to drive the addiction cycle.

1 Jun 2016

UCLA scientists discover cystatin E/M protein that can inhibit cervical cancer growth

UCLA scientists have identified a protein that has the potential to prevent the growth of cervical cancer cells. The discovery could lead to the development of new treatments for the deadly disease.

1 Jun 2016

First large-scale proteogenomic study helps pinpoint genes that drive breast cancer

Building on data from The Cancer Genome Atlas project, a multi-institutional team of scientists has completed the first large-scale "proteogenomic" study of breast cancer, linking DNA mutations to protein signaling and helping pinpoint the genes that drive cancer.

26 May 2016

Researchers discover new potential treatment target for liver cancer

Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer.

24 May 2016

Chemical compound eCF506 may be highly effective at blocking growth of breast cancer cells

A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.

24 May 2016

Malicious form of ATF2 protein drives formation of melanoma

An international collaborative study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a malicious form of a protein that drives the formation of melanoma.

20 May 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016.

20 May 2016

$Allogeneic HSCT offers good survival for select TKI-refractory CML patients$

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests.

18 May 2016

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study.

18 May 2016

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.

18 May 2016

CML treatment-free remission criteria outlined

Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy.

18 May 2016

Biovica acquires cSens AB - creating opportunities for solving cancer diagnostic challenges

Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness.

18 May 2016

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms.

17 May 2016

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

16 May 2016

Kinase News and Research

Defects in cerebrospinal fluid flow may contribute to scoliosis during adolescence

Researchers identify promising new compound for targeting triple-negative breast cancer

New study identifies PDGFRα as key molecule for HCMV viral entry

Researchers prove existence of olfactory receptor in pigment-producing skin cells

Mayo study finds mechanism by which Pten safeguards against tumor formation

Analysing blood metabolites may help monitor effects of novel drugs

Understanding how opiates affect brain pathways to drive addiction cycle

UCLA scientists discover cystatin E/M protein that can inhibit cervical cancer growth

First large-scale proteogenomic study helps pinpoint genes that drive breast cancer

Researchers discover new potential treatment target for liver cancer

Chemical compound eCF506 may be highly effective at blocking growth of breast cancer cells

Malicious form of ATF2 protein drives formation of melanoma

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Real-world CML management in line with ELN guidelines

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

CML treatment-free remission criteria outlined

Biovica acquires cSens AB - creating opportunities for solving cancer diagnostic challenges

Novel therapeutic approach to treat leukaemia patients

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News